| __timestamp | Amphastar Pharmaceuticals, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 1244910 |
| Thursday, January 1, 2015 | 46974000 | 5029636 |
| Friday, January 1, 2016 | 47298000 | 4846776 |
| Sunday, January 1, 2017 | 50918000 | 5329003 |
| Monday, January 1, 2018 | 58044000 | 7121000 |
| Tuesday, January 1, 2019 | 63109000 | 9128000 |
| Wednesday, January 1, 2020 | 65157000 | 10731000 |
| Friday, January 1, 2021 | 68920000 | 10701000 |
| Saturday, January 1, 2022 | 66592000 | 16121000 |
| Sunday, January 1, 2023 | 80393000 | 37021000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, operational costs are a critical factor in determining a company's financial health. Over the past decade, from 2014 to 2023, Amphastar Pharmaceuticals, Inc. and Viking Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Amphastar's SG&A expenses have consistently grown, peaking at approximately 80 million in 2023, marking a 99% increase from 2014. In contrast, Viking Therapeutics started with a modest 1.2 million in 2014, but by 2023, their expenses surged to nearly 37 million, a staggering 2,870% increase. This dramatic rise reflects Viking's aggressive expansion and investment in operational capabilities. As these companies navigate the competitive landscape, understanding their cost structures provides valuable insights into their strategic priorities and market positioning.
Novo Nordisk A/S vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amgen Inc. vs Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Viking Therapeutics, Inc.
Comparing SG&A Expenses: Genmab A/S vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Incyte Corporation and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Amphastar Pharmaceuticals, Inc.
Opthea Limited or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and MorphoSys AG
Viking Therapeutics, Inc. and Evotec SE: SG&A Spending Patterns Compared
Amphastar Pharmaceuticals, Inc. and Xencor, Inc.: SG&A Spending Patterns Compared